Evaluation of Predictability for Vancomycin Dosage Regimens by the Bayesian Method with Japanese Population Pharmacokinetic Parameters.

Teramachi, Hitomi; Hatakeyama, Hiromi; Matsushita, Ryo; Imai, Yukio; Miyamoto, Ken‐ichi; Tsuji, Akira

doi:10.1248/bpb.25.1333

Cited by 14 publications

(9 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[5][6][7] Pharmacokinetic studies of VAN in MRSAinfected patients have been reported, [8][9][10][11] and there are also reports of population pharmacokinetic parameters in adult Japanese patients. 12) Recently, an empirical Bayesian method was widely applied to TDM data 13) and the predictability of the Bayesian forecasting methods using population pharmacokinetic parameters of Japanese patients has been examined. 14,15) There is a phenomenon of increased renal clearance, known as augmented renal clearance (ARC).…”

Section: Introductionmentioning

confidence: 99%

Augmented Renal Clearance of Vancomycin in Hematologic Malignancy Patients

Izumisawa

Kaneko

Soma

et al. 2019

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

The pharmacokinetics of vancomycin (VAN) was retrospectively examined based on trough concentrations at large scale to identify pharmacokinetic differences between Japanese hematologic malignancy and non-malignancy patients. Data from 261 hematologic malignancy patients and 261 non-malignancy patients, including the patient's background, VAN dose, and pharmacokinetics of VAN estimated by an empirical Bayesian method, were collected and analyzed. Our results showed significantly higher values for VAN clearance and shorter elimination half-lives in patients with hematologic malignancies than non-malignancy patients. In addition, multiple regression analysis under adjusting for confounding factors by propensity score, showed that VAN clearance significantly increased in relation to hematologic malignancies. In conclusion, since in hematologic cancer patients VAN clearance is increased, the blood concentration of VAN becomes lower than expected and this may contribute to the survival of resistant bacteria when VAN is administered at low doses. These results suggest that early monitoring of VAN levels in hematologic cancer patients might be recommended to maintain desired effects without side-effects.

show abstract

Section: Introductionmentioning

confidence: 99%

Augmented Renal Clearance of Vancomycin in Hematologic Malignancy Patients

Izumisawa

Kaneko

Soma

et al. 2019

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

show abstract

“…With TDM data using Bayesian analysis (5, 6), parameters are calculated to determine a drug administration schedule that is based on patient‐specific pharmacokinetics. There have already been several studies comparing the prediction accuracy between population pharmacokinetic (PPK) analysis based on mean population parameters and Bayesian analysis, which demonstrated the extremely good accuracy of prediction using both methods (7–9) and clinical utility (10). However, there have been no studies comparing the prediction accuracy of concentrations estimated using Bayesian analysis‐based patient‐specific parameters with measured concentrations.…”

Section: Introductionmentioning

confidence: 99%

ORIGINAL ARTICLE: Investigation of the prediction accuracy of vancomycin concentrations determined by patient-specific parameters as estimated by Bayesian analysis

Hiraki

Onga

Mizoguchi

et al. 2010

Journal of Clinical Pharmacy and Therapeutics

View full text Add to dashboard Cite

show abstract

“…11) More recently, an empirical Bayesian method has been widely applied to TDM data, 12) and the predictability of the Bayesian forecasting methodology for vancomycin with the population pharmacokinetic parameters in Japanese patients was examined. 13,14) Vancomycin is mainly eliminated into urine, and most of the pharmacokinetic variability can be explained by the degree of renal function. 15) However, there have been several reports of a difference in vancomycin pharmacokinetics between malignant and non-malignant adult 7,10) and pediatric [16][17][18] patients, suggesting malignant state to be a covariate of the pharmacokinetic variability.…”

mentioning

confidence: 99%

A Retrospective Analysis of Vancomycin Pharmacokinetics in Japanese Cancer and Non-cancer Patients Based on Routine Trough Monitoring Data

Omote

Yano

Hashida

et al. 2009

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

The pharmacokinetics of vancomycin was retrospectively examined based on trough concentrations obtained during routine therapeutic drug monitoring to examine possible pharmacokinetic differences between adult Japanese cancer and non-cancer patients with various degrees of renal function. A total of 231 data points from 65 cancer patients and 41 non-cancer patients were collected, and patients' background, vancomycin dose, and vancomycin clearance estimated by an empirical Bayesian method were summarized. Regarding the patients' characteristics and clinical laboratory test data, no clear differences were found between the two groups. The relationship between vancomycin clearance and creatinine clearance were similar between the groups, suggesting little effect of malignancy on vancomycin clearance. After the sub-group comparisons regarding fluid retention and cancer type, no clear differences were found in the vancomycin clearance versus creatinine clearance relationship. We conclude that the initial dose of vancomycin should not necessarily be adjusted for cancer patients. For individualized vancomycin-based therapy, dose adjustment at the appropriate time is important according to information from routine therapeutic drug monitoring and clinical laboratory tests, and to observations of the efficacy, nephrotoxicity, and other conditions in each patient.

show abstract

Evaluation of Predictability for Vancomycin Dosage Regimens by the Bayesian Method with Japanese Population Pharmacokinetic Parameters.

Cited by 14 publications

References 13 publications

Augmented Renal Clearance of Vancomycin in Hematologic Malignancy Patients

Augmented Renal Clearance of Vancomycin in Hematologic Malignancy Patients

ORIGINAL ARTICLE: Investigation of the prediction accuracy of vancomycin concentrations determined by patient-specific parameters as estimated by Bayesian analysis

A Retrospective Analysis of Vancomycin Pharmacokinetics in Japanese Cancer and Non-cancer Patients Based on Routine Trough Monitoring Data

Contact Info

Product

Resources

About